The patient is not receiving therapy in a concurrent clinical study and the patient agrees not to participate in other interventional clinical studies during their participation in this trial while on study treatment. Patients participating in surveys or observational studies are eligible to participate in this study.
Eligibility criteria to participate in group  of the pilot study of the AYA-Hears instrument \r\nNote: participants in group  will not receive protocol-directed therapy
As of Amendment , if the registering site is a photon center (registering patients to group I), the patient must agree to participate in the advanced imaging sub-study
A female is eligible to enter and participate in this study if the following apply:
Has any other reason(s) for the investigator to consider that the subject should not participate in the study.
All patients have to agree to participate in the correlative study of sample collection for immune correlative assays in order to participate in the main study; however, if the sample cannot be obtained due to feasibility issues, the patient will be allowed to continue on treatment
Patients will be strongly encouraged to participate in -C-; if a patient does not agree to enroll on -C-, germline genetic analysis will not be performed
The patient is not receiving therapy in a concurrent clinical study and the patient agrees not to participate in other interventional clinical studies during their participation in this trial while on study treatment. Patients participating in surveys or observational studies are eligible to participate in this study.
Participant agrees not to participate in another interventional study while on treatment. Randomization Inclusion Criteria
Participant is willing and able to participate for the duration of the study
Participates or intends to participate in another drug study (other than observational studies) during the study
Clinical judgment by the investigator that the patient should not participate in the study
TREATMENT WITH SJCAR: Agreement to participate in long-term follow-up on protocol NCT
Patients from outside of the United States may participate in the study
Patients unable to read/write in English are eligible to participate in the overall study but will not participate in the patient-reported outcome questionnaires throughout the trial.
Subjects willing to participate in the study for at least  months
Both pediatric and adult patients can be eligible to participate
IMMUNE RECONSTITUTION STUDY ONLY: Decline to participate in the main trial, or main trial closed to accrual due to safety review
Clinical judgment by the investigator that the patient should not participate in the study
Patients with HM, as previously defined, without confirmed response to standard, first-line antineoplastic therapy, and/or who do not fulfill all Inclusion Criteria as stated, will be ineligible to participate in this study.
Agree to participate in biopsy of metastatic lesion during the study at day 
Must consent to participate in study I : Roswell Park Cancer Institute (RPCI) Data Bank and Biorepository (DBBR)
Subject must be capable and reliable to participate in all study related procedures
Patients in the expansion cohort must also agree to participate in the biomarker study. However, patients in the Melanoma KIT positive mutant subgroup, patients must agree to participate in the biomarker study and biopsies.
It is expected that five types of patients afflicted with EBV-associated lymphomas, lymphoproliferative disease or malignancies will be referred and will consent to participate in this trial; these are:
Willingness to participate in rigorous neurocognitive evaluations at baseline and serially following treatment
THE PATIENT IS INELIGIBLE TO PARTICIPATE IN PART  IF ANY OF THE FOLLOWING OCCUR: PDX data are non-informative.
THE PATIENT IS INELIGIBLE TO PARTICIPATE IN PART  IF ANY OF THE FOLLOWING OCCUR: Tumors do not engraft in the mice or do not respond to any of the selected agents.
THE PATIENT IS INELIGIBLE TO PARTICIPATE IN PART  IF ANY OF THE FOLLOWING OCCUR: Any other exclusion criteria set forth by individual treatment protocol of the active clinical trial(s) through which patients are going to be treated.
Psychosocial circumstances that preclude the patient being able to go through transplant or participate responsibly in follow up care
Any other reason the investigator considers the patient should not participate in the\n             study
Willing to participate in associated correlative science biomarker study
Willing to participate in associated correlative science biomarker study
Subject agrees not to participate in another interventional study while on treatment.
Patients must be offered the opportunity to participate in the ultra pure Circulating Tumor Cells (upCTCs) study
Subject agrees not to participate in another interventional study while on treatment.
Patients who have had a local MGMT testing that is unmethylated are not allowed to participate
Patients already receiving treatment with FOLFIRINOX +/- trastuzumab may participate in the study and have their data collected retrospectively if they met inclusion criteria at the start of therapy and sign consent for study participation moving forward
A female subjects is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
Subject agrees not to participate in another interventional study while on treatment.
Eligibility to a higher priority trial for first line or recurrent endometrial cancer (unless patient is unwilling to participate in such a trial)
Subject agrees not to participate in another interventional study while on treatment.
Subject agrees not to participate in another interventional study while on treatment.
Subject agrees not to participate in another interventional study while on treatment.
Mayo Clinic Arizona only: Willing to participate in associated biobanking study, -; the patient must sign consent to enroll onto the mandatory companion biobanking study in order to participate in this treatment study
Mayo Clinic Rochester and Florida only: Willing to participate in associated biobanking study, -; the patient must sign consent to enroll onto the mandatory companion biobanking study in order to participate in this treatment study
Enrollment in another interventional study.
Consent to participate in Data Bank and BioRepository (DBBR) (Roswell Park Cancer Institute [RPCI] only)
Subject agrees not to participate in another interventional study while on treatment.
Any other reason the investigator considers the patient should not participate in the study
Subject agrees not to participate in another interventional study while receiving study drug and participating in the present study.
Ability to participate in the clinical study for a minimum of at least  cycles ( weeks).
Women who participate in this study must agree not to breastfeed from study entry to a period of no less than four months post the HSV injection
Patients should not participate in any other therapeutic investigational study while taking part in this study
Willing and able to give informed consent and participate in study procedures as described in the PLK and PLK protocols. Patients consented for PLK will also be asked to participate in the PLK PROCLAIM registry study.
Received investigational drug within  days prior to study dosing. Patients may participate in non-interventional or observational clinical studies, including the PLK PROCLAIM registry study.
To the best of his or her (or parent/guardian) knowledge, willing and able to participate in all required study activities for the duration of the study.
Subject agrees not to participate in another interventional study while on treatment.
The patient is not receiving therapy in a concurrent clinical study and the patient agrees not to participate in other interventional clinical studies during their participation in this trial while on study treatment. Patients participating in surveys or observational studies are eligible to participate in this study.
Subject agrees not to participate in another interventional study while on treatment.
Subject agrees not to participate in another interventional study while on treatment
Clinical judgement by the investigator that the patient should not participate in the study
Subjects can participate in the study if in the opinion of the investigator it is thought not to affect the subject's safety, the conduct of the study or the interpretation of the data.
Patient desires not to participate in the study.
Subject agrees not to participate in another interventional study while on treatment.
Only one subject per household may participate
Males are not permitted to participate
KEY INFORMANT: Agrees to participate in a confidential -on- semi-structured interview with the research team
KEY INFORMANT: Unwilling to participate
FOCUS GROUPS:\r\n* Has a household member who has already participated (or agreed to participate)
Have parental consent to participate
Subject agrees not to participate in another interventional study while on treatment.
(Physician participation) willing to participate in the study
Able to participate safely in all program sessions
Cognitively able to consent to participate
Be mentally and physically able to participate in the study
PATIENT ONLY: Having a spouse/romantic partner (including same-sex) and who is willing to participate
Able to understand the description of the study and willing to participate
The patient and co-parent must agree to focus on the same child throughout the study and consent to have the child participate before the child's assent will be sought
Patients with severe cognitively impairments or who appear too weak, emotionally distraught, agitated or ill to participate, as judged by either the research study staff or an oncology provider, will be excluded
INCLUSION CRITERIA FOR PARENTS: Cognitively able to participate in interactive interviews
EXCLUSION CRITERIA FOR PARENTS: Parent is cognitively or physically unable to participate in interactive interview
Physician verification of ability to participate in the intervention
Physically and cognitively able to participate in the study as determined by the investigators
HSCT CGs: Physically and cognitively able to participate in the study as determined by the investigators
Physically and cognitively unable to participate in the study as determined by the investigators
HSCT CGs: Physically and cognitively unable to participate in the study as determined by the investigators
Clinician inclusion criteria:\r\n* Oncology staff nurses who undergo training to deploy CONNECT, oncologists, and practice managers at participating sites will be eligible to participate
Willing to come to MD Anderson (MDA) for the therapy sessions; or willing to participate in the therapy sessions at their homes and live within a  minute drive of MDA main campus; or can participate in the therapy sessions from one of MDAs Regional Care Centers
Contra-indications to resistance training or protein supplementation (e.g. renal) (physicians will verify if they can participate)
Subject must be capable and reliable to participate in all study related procedures
Be willing to provide written informed consent to participate in the study which includes several clinical evaluations, provide access to medical records/primary care physician (PCP), and allow all interviews and PSST therapy sessions to be audiotaped.
PATIENTS: Willingness to participate in all study activities including data collection
FCGs: Willingness to participate in study activities including data collection
Only requirement for organ function is for patients to have competency to consent and participate in the study; in the arm of the study which requires patients to have olfactory dysfunction before enrollment, an UPSIT score will be used to identify these patients
Participate in the specified study visits and laboratory testing including three ( mL) blood draws and three  hour urine collections
Ability to safely participate in outpatient rehabilitation program
Unable to safely participate in outpatient rehabilitation
All couples co-habiting for at least  years with current partner who is willing to participate in study
Cognitively able to participate in interactive interviews
Cognitively or physically unable to participate in interactive interview
Able to understand the description of the study and willing to participate
Patient is willing to participate in this study
Participants with serious or unstable illness, as determined by study physicians and clinicians, may be deemed unfit to participate
Willing to participate in the guided and home yoga practice
Patients on stable doses (defined as same dose for  weeks) of dexamethasone, mirtazapine, zolpidem, benzodiazepines, phenothiazines are allowed to participate in the study
One consistent parent is willing and available to participate in all parent and evaluation sessions
Physically unable to participate in the study
have the permission of their oncologists to participate.
Any woman currently pregnant will not be eligible, but may participate  or more\n             months after the end of her pregnancy if the study is still ongoing
Have a stable partner for six months who is willing to participate
Able and willing to participate in an art therapy session at Maroone Cancer Center
Spouses/partners could not participate if the patient refused participation
Become unable to participate in a fully app and web-based intervention trial
Physician approval to participate in intervention
Able to participate occasionally in mildly strenuous physical effort
Patients must be offered the option to participate in the Diet and Lifestyle Substudy
Women who are using postmenopausal hormones, and are planning to continue the same regimen through the study intervention are eligible to participate
Individuals who are unable to participate in cycling due to musculoskeletal limitations.
Patients who are being screened for the therapeutic clinical trial will also be approached for participation into the optional sub-study evaluating sociobiological response to stress; refusal to participate in the sub-study will not impact the patients eligibility to participate in the therapeutic intervention\r\n* Should a patient consent to the optional sub-study, the patient may proceed with the optional baseline interventions for the optional sub-study as outlined within the protocols study calendar
Multiple members of the same household cannot participate.
Willing to participate in all study components
Women currently on hormonal contraception (i.e., oral contraceptives, Mirena intrauterine device [IUD]) are eligible to participate if they have been on a stable dose for at least  months; women who have undergone bilateral tubal ligation are also eligible to participate in this study; there will be stratification for hormonal contraceptive use within  months prior to registration
LGBT SUB-STUDY: Participants who complete the screener, are willing to participate in a longitudinal study for one year, and who self-identify as lesbian, gay, bisexual or transgender will be eligible to participate in the cohort study
PARTICIPANTS: Are willing to participate in a study about health behaviors involving nutrition or CRC screening
Ambulatory, able to come to either food distribution site to pick up food and participate in clinical examinations and laboratory tests
general conditions in which subjects are not suitable to participate in the study
Individuals who have any of the following will not be eligible to participate:
Willingness to participate in collection of pharmacokinetic samples
Patients who do not wish to participate
Subjects must be eligible for and willing to participate and sign consent for National Cancer Institute (NCI) protocol -C-: Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults with Neurofibromatosis Type , for the clinical evaluation necessary for this study
Pregnancy; regular clinical practice already excludes pregnant patients from gadolinium contrast; the current clinical practice will be applied - patients will be verbally screened and asked if they think they could be pregnant; if the answer is yes, then the patient will be excluded from the study; if the patient is uncertain about the pregnancy status, she will be given an option to undergo a pregnancy test or not participate in the study altogether; patients who self-report that they are not pregnant will be allowed to participate in the study; this procedure is based on current department policy guidelines
Subjects will be selected on the basis of their willingness and ability to participate and on their likelihood of completing the study
Any patient under age  may only participate in T imaging
Patients under the age of  may not participate in T imaging
Subject agrees not to participate in another interventional study while on treatment.
Ability to travel to appointments and willingness to participate in this study
Patients who will undergo IVU using digital tomosynthesis and staging abdomino-pelvic CT as part of their routine care, will be invited to participate in this study
Patients who have been referred for CTU will also be invited to participate in the study
Subjects who are willing to participate
Participant is willing to participate in the educational component of this project
OHSU Radiation Medicine department has agreed to participate as pilot department for this project; all active Radiation Medicine providers are requested to participate in the training; providers have the option to not participate
Patients who do not verbally, written, or electronically consent to participate (usability test and RCT)
Those who do not wish to participate
Health care providers at the participating site must be willing and able to participate in the educational initiative